PharmiWeb.com - Global Pharma News & Resources
01-Jul-2020

Xlife Sciences AG: Xlife Sciences waives early redemption of the privately placed convertible bond until July 1, 2023


DGAP-Media / 01.07.2020 / 12:00

This is intended to ensure that the largest amount of shares possible remain tradable and in free float.

About Xlife Sciences AG

Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch



End of Media Release


Issuer: Xlife Sciences AG
Key word(s): Finance

01.07.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Z├╝rich
Switzerland
Phone: 0041 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Listed: Regulated Unofficial Market in Frankfurt, Munich
EQS News ID: 1083163

 
End of News DGAP Media

Editor Details

Last Updated: 01-Jul-2020